The role of upregulation of the ACE-2 receptors by ACE inhibitors and angiotensin II receptor blockers used in the management of hypertension, diabetes, and CKD [31] also requires further exploration in elucidating the metabolic pathways that underpin the relationship between these co-morbidities and increased SARS-CoV-2 related severe morbidity and mortality. The gene discussed is ACE; the disease is chronic kidney disease.